Clinical Trial Update: Melphalan, Thalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed, Previously Untreated Primary Systemic Amyloidosis [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating the combination of melphalan, thalidomide, and dexamethasone in patients with newly diagnosed primary systemic AL amyloidosi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Al Amyloidosis

Drugs mentioned

• Alkeran (melphalan)
• Decadron (Dexamethasone)
• Thalomid (thalidomide)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Multiple Myeloma and Plasma Cell Neoplasm | Phase 2 | Status: COMPLETED